SCHEMBL7070928

SCHEMBL7070928

CCCN1CCC(C#N)(NC(=O)C(CC(C)(C)C)NC(=N)N2CCOCC2)CC1

nearest known ligand 0.53

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CTSS P25774 20/20 0.53
CTSL P07711 2/20 0.47
CTSB P07858 13/20 0.45
CTSK P43235 13/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6107557 0.91 CTSS (0.64) CTSSCTSLCTSBCTSK
SCHEMBL6111527 0.86 CTSS (0.50) CTSSCTSLCTSBCTSK
SCHEMBL6111534 0.86 CTSS (0.50) CTSSCTSLCTSBCTSK
SCHEMBL6108152 0.85 CTSS (0.62) CTSSCTSLCTSBCTSK
SCHEMBL6105582 0.85 CTSS (0.60) CTSSCTSLCTSBCTSK
SCHEMBL6968079 0.84 CTSS (0.48) CTSSCTSLCTSBCTSK
SCHEMBL6107298 0.84 CTSS (0.61) CTSSCTSLCTSBCTSK
SCHEMBL7220139 0.84 CTSS (0.49) CTSSCTSLCTSBCTSK
SCHEMBL6106433 0.84 CTSS (0.60) CTSSCTSLCTSBCTSK
SCHEMBL8256768 0.83 CTSS (0.62) CTSSCTSLCTSBCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225270-A1 Compounds useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2003-12-04 US disclosed
US-20030225271-A1 Compounds useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-12-04 US disclosed
US-20020058809-A1 Compounds useful as reversible inhibitors of cysteine proteases EMMANUEL MICHEL JOSE (US) 2002-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058809-A1 Compounds useful as reversible inhibitors of cysteine proteases CTSS, CTSK, CTSB CTSS 1/4885CTSL 9/4885CTSB 3/4885
US-20030225270-A1 Compounds useful as reversible inhibitors of cysteine proteases CTSS, CTSK, CTSB CTSS 1/4885CTSL 9/4885CTSB 3/4885
US-20030225271-A1 Compounds useful as reversible inhibitors of cysteine proteases CTSS, CTSK, CTSB CTSS 1/4885CTSL 9/4885CTSB 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.